The adoption of organoids is expected to transform the development of cancer drugs. Organoids, which are miniaturized patient-derived models, may be used for personalized medicine and drug screening to predict cancer treatment responses. The growth of the human organoids market and advancements in related technologies, such as next-generation sequencing, are reportedly gaining momentum.